# Bringing value to cancer research

## TL;DR

This paper suggests expanding the definition of value in cancer trials to include patient experiences and costs, aiming for better, more patient-centered care.

## Contribution

A novel framework integrating oncologic outcomes, patient-reported outcomes, and cost analyses for value-based decision-making in cancer care.

## Key findings

- Current cancer trials often overlook patient-reported outcomes like quality of life and financial burden.
- A multidimensional visual tool, such as a radar chart, can support value-based shared decision-making.
- Standardizing value assessment could lead to more equitable and effective cancer care.

## Abstract

This article argues for incorporating a broader definition of “value” into cancer clinical trials. Current trials primarily focus on efficacy and safety, neglecting patient-reported outcomes (PROs) such as quality of life, financial toxicity, and time burden, as well as cost-effectiveness. We propose a novel framework integrating oncologic outcomes, PROs, and cost analyses. We also propose a multidimensional visual tool, such as a radar chart, to facilitate better-informed, value-based shared decision-making. This requires a collaborative approach, involving stakeholders in defining value metrics. While acknowledging challenges such as increased administrative burden and data interpretation complexities, a comprehensive framework can substantially improve patient-centered cancer care. The ultimate goal is to standardize value assessment in cancer research, leading to more equitable and effective care.